1
|
Kellogg MA, Ernst LD, Spencer DC, Datta P, Klein E, Bhati MT, Shivacharan RS, Nho YH, Barbosa DAN, Halpern CH, Raslan A. Dual Treatment of Refractory Focal Epilepsy and Obsessive-Compulsive Disorder With Intracranial Responsive Neurostimulation. Neurol Clin Pract 2024; 14:e200318. [PMID: 38846467 PMCID: PMC11152646 DOI: 10.1212/cpj.0000000000200318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 04/02/2024] [Indexed: 06/09/2024]
Abstract
Purpose of the Review Intracranial neurostimulation is a well-established treatment of neurologic conditions such as drug-resistant epilepsy (DRE) and movement disorders, and there is emerging evidence for using deep brain stimulation to treat obsessive-compulsive disorder (OCD) and depression. Nearly all published reports of intracranial neurostimulation have focused on implanting a single device to treat a single condition. The purpose of this review was to educate neurology clinicians on the background literature informing dual treatment of 2 comorbid neuropsychiatric conditions epilepsy and OCD, discuss ethical and logistical challenges to dual neuropsychiatric treatment with a single device, and demonstrate the promise and pitfalls of this approach through discussion of the first-in-human closed-looped responsive neurostimulator (RNS) implanted to treat both DRE (on-label) and OCD (off-label). Recent Findings We report the first implantation of an intracranial closed-loop neurostimulation device (the RNS system) with the primary goal of treating DRE and a secondary exploratory goal of managing treatment-refractory OCD. The RNS system detects electrophysiologic activity and delivers electrical stimulation through 1 or 2 electrodes implanted into a patient's seizure-onset zones (SOZs). In this case report, we describe a patient with treatment-refractory epilepsy and OCD where the first lead was implanted in the right superior temporal gyrus to target the most active SOZ based on stereotactic EEG (sEEG) recordings and semiology. The second lead was implanted to target the right anterior peri-insular region (a secondary SOZ on sEEG) with the distal-most contacts in the right nucleus accumbens, a putative target for OCD neurostimulation treatment. The RNS system was programmed to detect and record the unique electrophysiologic signature of both the patient's seizures and compulsions and then deliver tailored electrical pulses to disrupt the pathologic circuitry. Summary Dual treatment of refractory focal epilepsy and OCD with an intracranial closed-loop neurostimulation device is feasible, safe, and potentially effective. However, there are logistical challenges and ethical considerations to this novel approach to treatment, which require complex care coordination by a large multidisciplinary team.
Collapse
Affiliation(s)
- Marissa A Kellogg
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Lia D Ernst
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - David C Spencer
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Proleta Datta
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Eran Klein
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Mahendra T Bhati
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Rajat S Shivacharan
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Young-Hoon Nho
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Daniel A N Barbosa
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Casey H Halpern
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| | - Ahmed Raslan
- Department of Neurology and Comprehensive Epilepsy Center (MAK, LDE, DCS, PD, EK), Oregon Health & Science University (OHSU); Department of Neurology (MAK, LDE, EK), Portland Veterans Affairs Healthcare System, OR; Department of Psychiatry and Behavioral Sciences (MTB); Department of Neurosurgery (MTB, RSS), Stanford University School of Medicine, CA; Department of Neurosurgery (Y-HN, DANB, CHH), University of Pennsylvania; Department of Surgery (CHH), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA; and Department of Neurosurgery and Comprehensive Epilepsy Center (AR), Oregon Health & Science University (OHSU) Department of Neurosurgery, Portland, OR
| |
Collapse
|
2
|
Abounoori M, Maddah MM, Akbari E, Houshmand G, Ardeshiri MR. The Effect of Orexin Receptor Antagonism on Quinpirole-Induced Compulsive-Like Checking Behavior in Rats. Neurotox Res 2020; 38:18-26. [PMID: 32207079 DOI: 10.1007/s12640-020-00196-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 03/11/2020] [Accepted: 03/16/2020] [Indexed: 12/31/2022]
Abstract
The orexinergic system supposedly plays a role in stress circuits for arousing behaviors during anxiety, suggesting that it may play a role also in neural circuits mediating the compulsive behavior characteristic of obsessive-compulsive disorder (OCD). This study aims to investigate the roles of the orexinergic system in the development of OCD behaviors, using as preparation the induction of compulsive checking by chronic treatment with the D2/D3 agonist, quinpirole. Repeated injections of quinpirole (0.5 mg/kg, twice per week for a total of 10 injections) were used to induce compulsive checking. In separate groups of rats, OX1R (SB334867-A; 10 μg i.c.v) and OX2R (TCS-OX2-29; 10 μg i.c.v) receptor antagonists were co-administered together with quinpirole. Checking behavior in a large open field was measured after the first, fifth, and tenth injections of the drugs. SB334867-A attenuated checking behavior and the level of anxiety. TCS-OX2-29 administration ameliorated anxiety but did not block the development of compulsive checking. Orexin 1 receptors seem to play a more critical role than orexin 2 receptors in the induction of compulsive checking. Considering that the quinpirole sensitization model of OCD involves activation of dopamine systems and sensitization to quinpirole, it is suggested that neural interaction between orexigenic and dopamine systems may be important in the pathogenesis of OCD.
Collapse
Affiliation(s)
- Mahdi Abounoori
- Medical Student, Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Mohammad Moein Maddah
- Medical Student, Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Esmaeil Akbari
- Immunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.,Department of Physiology, School of Medicine, Mazandaran University of Medical Sciences, P.O. Box: 481751665, Sari, Iran
| | - Gholamreza Houshmand
- Department of Pharmacology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Motahareh Rouhi Ardeshiri
- Immunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. .,Department of Physiology, School of Medicine, Mazandaran University of Medical Sciences, P.O. Box: 481751665, Sari, Iran.
| |
Collapse
|